The Newborn Screening (NBS) Market is projected to reach $2.07 billion by 2029, at a CAGR of 8.9% from 2022 to 2029. Newborn screening is performed for the early identification of the conditions that can affect the child’s survival or long-term health. The screening technology specifies a series of essential tests for early detection, health management, timely diagnosis, management and prevention of disabilities in newborns.